Lnc RNA SNHG20 participated in proliferation, invasion, and migration of breast cancer cells via miR-495.
作者： Yan-Xing Guan , Meng-zhi Zhang , Xue-Zhong Chen , Qing Zhang , Shao-Zheng Liu
DOI: 10.1002/JCB.26588
关键词:
摘要: To explore the mechanism of lnc SNHG20 in regulation proliferation, invasion, and migration breast cancer cells. mRNA levels SNHG20, miR-495, HER2 were detected by qRT-PCR. Protein level was measured Western blot. Cell CCK-8 assay, Boyden chamber Transwell assay. The combination between miR-495 confirmed RNA pull down luciferase report assays. We also established cancer-bearing mice model analyzed tumor volumes. Our data showed expression significantly upregulated, downregulated, upregulated tissues cell lines. Besides, promoted found negatively regulated could regulate HER2. Moreover, we discovered that via miR-495. cells miR-495/HER2. Finally, model. regulates to promote
sci-hub.se 参考文章(24)
Junyi Zhang, Rongcheng Luo, Aimin Li, Rong Li, Ling Qin, Special suppressive role of miR-29b in HER2-positive breast cancer cells by targeting Stat3 American Journal of Translational Research. ,vol. 7, pp. 878- 890 ,(2015)
Lola Rahib, Benjamin D. Smith, Rhonda Aizenberg, Allison B. Rosenzweig, Julie M. Fleshman, Lynn M. Matrisian, Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States Cancer Research. ,vol. 74, pp. 2913- 2921 ,(2014) , 10.1158/0008-5472.CAN-14-0155
Zhen Zhao, Rui Li, Sha Sha, Qiong Wang, Weidong Mao, Tao Liu, Targeting HER3 with miR-450b-3p suppresses breast cancer cells proliferation Cancer Biology & Therapy. ,vol. 15, pp. 1404- 1412 ,(2014) , 10.4161/CBT.29923
Melina Arnold, Henrike E. Karim-Kos, Jan Willem Coebergh, Graham Byrnes, Ahti Antilla, Jacques Ferlay, Andrew G. Renehan, David Forman, Isabelle Soerjomataram, Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. European Journal of Cancer. ,vol. 51, pp. 1164- 1187 ,(2015) , 10.1016/J.EJCA.2013.09.002
Ciara C. O’Sullivan, Karen L. Smith, Therapeutic Considerations When Treating HER2-positive Metastatic Breast Cancer Current Breast Cancer Reports. ,vol. 6, pp. 169- 182 ,(2014) , 10.1007/S12609-014-0155-Y
James A Lee, Megan Shaheen, Thomas Walke, Matt Daly, Clinical and health economic outcomes of alternative HER2 test strategies for guiding adjuvant trastuzumab therapy. Expert Review of Pharmacoeconomics & Outcomes Research. ,vol. 11, pp. 325- 341 ,(2011) , 10.1586/ERP.11.25
Ho-June Lee, Guanglei Zhuang, Yi Cao, Pan Du, Hyo-Jin Kim, Jeff Settleman, Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells Cancer Cell. ,vol. 26, pp. 207- 221 ,(2014) , 10.1016/J.CCR.2014.05.019
Sanjay Mishra, Amit Kumar Srivastava, Shankar Suman, Vijay Kumar, Yogeshwer Shukla, Circulating miRNAs revealed as surrogate molecular signatures for the early detection of breast cancer. Cancer Letters. ,vol. 369, pp. 67- 75 ,(2015) , 10.1016/J.CANLET.2015.07.045
Devika Gajria, Sarat Chandarlapaty, HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies Expert Review of Anticancer Therapy. ,vol. 11, pp. 263- 275 ,(2011) , 10.1586/ERA.10.226
Anthony Howell, Annie S Anderson, Robert B Clarke, Stephen W Duffy, D Gareth Evans, Montserat Garcia-Closas, Andy J Gescher, Timothy J Key, John M Saxton, Michelle N Harvie, None, Risk determination and prevention of breast cancer Breast Cancer Research. ,vol. 16, pp. 446- 446 ,(2014) , 10.1186/S13058-014-0446-2